Travelers’ Diarrhea Defined, Symptoms, & Treatment Options
This information is intended for U.S. residents only.
What is travelers’ diarrhea?
People get travelers’ diarrhea by eating food and drinking water that contain germs. People can get this illness in areas of the world where the drinking water is not clean.
Most travelers’ diarrhea cases begin abruptly. Usually, a traveler experiences four to five loose or watery bowel movements each day. Other common symptoms include nausea, vomiting, diarrhea,
abdominal cramping, bloating, fever, urgency, and malaise.
How common is travelers’ diarrhea?
Twenty to 50% of travelers may develop diarrhea depending on the region of the world they visit. In fact, diarrhea is the most common illness of travelers. Men and woman are at equal risk for developing
travelers’ diarrhea. In general, travelers at risk for diarrhea commonly come from industrialized nations and travel to high-risk areas that are primarily within developing or less industrialized
nations of the world, including Latin America, Africa, the Middle East and Asia. Areas of lesser risk include China and some Caribbean nations. Travel to areas of the United States, Canada, Northern
Europe and Australia pose the lowest risk to travelers.
Risk areas for travelers’ diarrhea
Click here to download the map (PDF 2.6MB)
What are the symptoms of travelers’ diarrhea?
The symptoms of travelers’ diarrhea vary. Generally, diarrhea occurs within the first week of travel and lasts up to 3-4 days.
Treatment of travelers’ diarrhea
For patients diagnosed with travelers’ diarrhea, oral rehydration is often beneficial to replace lost fluids and electrolytes. Additionally, certain patient may
benefit from antibiotic therapy usually given
for 3-5 days. Antimotility agents can also be used to treat the symptoms of travelers’ diarrhea.
How does travelers' diarrhea affect gut flora imbalance?
Travelers' diarrhea is caused by pathogenic bacteria (eg, E. coli ) displacing healthy gut flora. The resulting pathogenic infection can cause mild or
severe inflammation of the gastrointestinal epithelium.1,2 The inflammation can disrupt the delicate balance between epithelium and gut flora.1
In some cases of travelers' diarrhea, this imbalance has been shown to lead to chronic gastrointestinal illness.1,3
How do conventional systemic antibiotics affect gut flora?
Conventional systemic antibiotics are effective in travelers' diarrhea, but can also cause disruptions to gut flora.4-6 These disruptions can be short- or long-term, with clinical studies showing that disruptions can last for up to 2 years.7,8
References
1. Okhuysen PC. Travelers' diarrhea, new insights. J Clin Gastroenterol. 2007;41(suppl 1):S20-S23.
2. Acute diarrhea. Cleveland Clinic. http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/gastroenterology/acute-diarrhea. Accessed August 6, 2009.
3. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol. 2004;99:1774-1778.
4. Huang DB, DuPont HL. Rifaximin—a novel antimicrobial for enteric infections. J Infec. 2005;50(2):97-106.
5. Okhuysen PC. Current concepts in travelers' diarrhea: epidemiology, antimicrobial resistance and treatment. Curr Opin Infect Dis. 2005;18:522-526.
6. Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology. 2009;136:2015-2031.
7. Phillips ML. Gut reaction. Environmental effects on the human microbiota. Environ Health Perspect. 2009;117(5):A199-A205.
8. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1(1):56-66.
Get Adobe Acrobat Reader
SAFETY CONSIDERATIONS
Xifaxan® (rifaximin) Tablets are indicated for the treatment of patients (≥12 years of age) with travelers’ diarrhea caused by noninvasive strains of
Escherichia coli. Xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. Xifaxan should be
discontinued if diarrhea symptoms get worse or persist more than 24-48 hours and alternative antibiotic therapy should be considered. Escherichia coli has been shown to develop resistance to rifaximin in vitro. However, the clinical significance of such an effect has not been studied.
In clinical trials, Xifaxan was generally well tolerated. The most common side effects (vs. placebo) were flatulence 11.3% (vs. 19.7%), headache 9.7% (vs. 9.2%), abdominal pain 7.2% (vs. 10.1%), rectal tenesmus 7.2%
(vs. 8.8%), defecation urgency 5.9% (vs. 9.2%) and nausea 5.3% (vs. 8.3%).
For complete Prescribing Information, please click here.
For product information, adverse event reports, and product complaint reports please call:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: